486422-57-5 Usage
General Description
4-(1-Pyrrolidinylsulfonyl)phenylboronic acid is a chemical compound that belongs to the class of organoboron compounds, which are organic compounds including the element boron. It is characterized by its sulfonamide group, which comprises a sulfur atom bonded to an oxygen atom and nitrogen atom, its boronic acid group, made up of boron linked to a hydroxyl group, and its heterocyclic pyrrolidine ring, which contains nitrogen. The chemical structure allows 4-(1-Pyrrolidinylsulfonyl)phenylboronic acid to participate in various kinds of chemical reactions, particularly those involving the formation or breakage of carbon-boron bonds. It's often used as a reagent in chemical synthesis and applications in the pharmaceutical and material science fields.
Check Digit Verification of cas no
The CAS Registry Mumber 486422-57-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,8,6,4,2 and 2 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 486422-57:
(8*4)+(7*8)+(6*6)+(5*4)+(4*2)+(3*2)+(2*5)+(1*7)=175
175 % 10 = 5
So 486422-57-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H14BNO4S/c13-11(14)9-3-5-10(6-4-9)17(15,16)12-7-1-2-8-12/h3-6,13-14H,1-2,7-8H2
486422-57-5Relevant articles and documents
Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimers Disease: Design, synthesis, and characterization of pyrazines
Berg, Stefan,Bergh, Margareta,Hellberg, Sven,Hoegdin, Katharina,Lo-Alfredsson, Yvonne,Soederman, Peter,Von Berg, Stefan,Weigelt, Tatjana,Ormoe, Mats,Xue, Yafeng,Tucker, Julie,Neelissen, Jan,Jerning, Eva,Nilsson, Yvonne,Bhat, Ratan
supporting information, p. 9107 - 9119,13 (2020/10/15)
Glycogen synthase kinase-3β, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism. Active forms of GSK3β localize to pretangle pathology including dystrophic neuritis and neurofibrillary tangles in Alzheimers disease (AD) brain. By using a high throughput screening (HTS) approach to search for new chemical series and cocrystallization of key analogues to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and bloo-brain barrier penetrance. The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimers disease.